m6A-Related lncRNA to Develop Prognostic Signature and Predict the Immune Landscape in Bladder Cancer

Figure 7

The risk model of m6A-related prognostic lncRNAs in bladder cancer. (a–b) Distribution of risk score of bladder cancer patients in training cohort and test cohort. (c–d) Survival status of each patient in training cohort and test cohort. (e–f) Heatmap about the expression of m6A-related prognostic lncRNAs in training cohort and test cohort.

(a)

(b)

(c)

(d)

(e)

(f)